FDA warns New Life Pharma over unapproved semaglutide and tirzepatide vials

FDA sent a warning letter dated April 14, 2026, to New Life Pharma LLC of Northvale, New Jersey, saying the company's "Semaglutide Sterile Multi-Dose Vial" and "Tirzepatide Sterile Multi-Dose Vial" are unapproved new drugs and that its manufacturing fell short of federal sterility and quality rules ^[1].

The letter, reference 320-26-65, was issued by FDA's Center for Drug Evaluation and Research to Arthur Leong, the company's director of QA ^[1]. It follows an inspection of the firm's facility at 265 Livingston Street from February 3 to February 13, 2026 ^[1].

What the letter says

FDA said no approved applications are in effect for either product, making them unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act ^[1]. The agency also called them misbranded because New Life Pharma did not properly register its facility or list the drugs with FDA, and had no labeler code ^[1]. The company registered as a contract manufacturer of human over-the-counter monograph drugs, but FDA said the inspection found it does not make any OTC monograph drugs ^[1].

The letter describes the products as lyophilized powder in sterile glass multi-dose vials with rubber stoppers, requiring reconstitution and injection ^[1]. FDA said the firm shipped them to weight loss clinics ("med spas") and cosmetic surgery practices, and in at least some cases included bacteriostatic water purchased online ^[1]. The labels carried a National Drug Code, the term "Rx-only" and "Sterile Multi-Dose Vial; Refrigerate after reconstitution," which FDA cited as evidence the products were intended for use as prescription drugs ^[1].

Sterility and quality failures

FDA listed manufacturing violations that included no aseptic processing simulations (media fills), no airflow visualization (smoke) studies, no cleaning validation and no routine environmental monitoring program ^[1]. It said the products were made under purported ISO 8 conditions without adequate microbiological and particulate data, which the agency said did not meet ISO 5 standards for aseptic operations ^[1]. FDA said this placed patients at serious risk of receiving non-sterile products, which it said could result in severe infections or other life-threatening complications ^[1].

The letter also said the quality unit failed to establish adequate production and process control procedures, test each component for identity and purity, test each batch for sterility and pyrogens, keep written cleaning and equipment maintenance procedures, or support expiration dates with stability testing ^[1]. FDA reviewed the company's March 6, 2026 response to a Form FDA 483 and called it inadequate ^[1].

Inspection access refused

FDA said its investigators were denied access during the inspection to two areas labeled "Area Not In Use," and that the company confirmed it was refusing access ^[1]. Under section 501(j) of the law, drugs are considered adulterated if they were made in an establishment that delayed, denied, limited or refused an FDA inspection ^[1]. FDA said its inspection authority extends to all areas of a drug manufacturing facility, including areas designated as not in use ^[1].

Why it matters for patients

Unapproved versions of these drugs are not the same as the FDA-approved brand products. FDA-approved semaglutide products include Ozempic, Wegovy and Rybelsus; approved tirzepatide products include Mounjaro and Zepbound. The vials named in this letter are not FDA-approved, and FDA's stated concern here centers on sterility, meaning whether a product a patient injects is free of contamination.

An injectable made without validated sterile controls can introduce bacteria directly into the body, and the letter says the risk includes severe infection. The letter does not describe any patient illnesses linked to these specific products, and it does not say how many vials were shipped, to which clinics, or over what period. It also does not say whether any patients received them.

What happens next

The letter states FDA's position; a warning letter is not a court order and does not by itself require the company to stop selling. The letter does not state what deadline, if any, FDA set for the company's reply, and it does not say whether the company has responded to the April letter. A recall, product seizure, injunction or patient injury report tied to these products has not been reported ^[1].